EUVIMED · CrossrefZeitschrift
Psychedelics
ISSN 2997-268X · Genomic Press
Neueste Artikel
Exploring cancer neuroscience with psychedelics: Brain-body crosstalk, neuroimmune modulation, and implications from tumor biology to end-of-life support
Psychedelics and time: Exploring altered temporal perception and its implications for consciousness, neuroscience, and therapy
Exploring the therapeutic potential of psychedelics: Fear extinction mechanisms and amygdala modulation
Peripheral signals, central questions: Examining the relationship between psychedelics and brain-derived neurotrophic factor (BDNF)
Psilocybin-assisted psychotherapy: Advancements, challenges, and future directions for treating resistant depression
Psychedelics: The Journal of Psychedelic and Psychoactive Drug Research – Charting a new course in psychedelic science
Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help
Effects of ayahuasca on fear and anxiety: cross-talk between 5HT1A and 5HT2A receptors
Katarina Leão: Links between the auditory and limbic systems, with a focus on the effects of unconventional novel treatment options, such as psychedelics and cannabis extract
Bernard Lerer: Pre-clinical, translational and clinical research focused on the use of psychedelic drugs and their derivatives to treat psychiatric disorders
Charles L. Raison: Elucidating the role of conscious experience in the therapeutic effects of psychedelics as a means to optimize clinical outcomes
Nicolas Garel: Combining psychoactive molecules and psychotherapy for patients suffering from mood and substance use disorders: a new therapeutic paradigm
Stephanie Knatz Peck: Novel and innovative treatment for eating disorders
Alaina M. Jaster: Bridging the gap across preclinical and clinical disciplines in the psychedelic sciences
Fayzan Rab: What are the economic and public health implications of psychedelic therapies?
An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States
Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder
Reading the crowd: attitudes toward psychedelics and psychedelic therapies among attendees at a conference
Counting the uncountable: The critical quest to quantify psychedelic medicine's reach
Psychedelics, Yes—but Not Only: Redefining the boundaries of consciousness research as part of humanity's ongoing attempt to transcend our incompleteness
From compulsive behaviors to psychedelic therapeutics: When mice and man speak the same circuit language
MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions
Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence
Michael A. Wheeler: Psychedelics and neuroimmune circuits—what a strange trip, indeed
Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders
Erin Mauney: Psychedelics as modulators of the gut-brain interaction
Deanna M. Kaplan: Listening to daily life: exploring speech data, shared meaning, and generative artificial intelligence (AI) in clinical science
Claire Foldi: Unravelling the neurobiology of eating disorders to inform effective treatments
Harriet de Wit: What can we learn about behavior and brain processes by studying psychoactive drugs in humans? How can we harmonize behavioral research in humans and nonhuman species?
Gregor Hasler: Three Guiding Questions — How do psychedelics shape the brain? How can they heal psychiatric disorders such as depression and PTSD? How can we ensure their safe and responsible use?
EUVIMED